
Quarterly report 2022-Q4
added 02-09-2023
Cardiovascular Systems Long-Term Debt 2011-2026 | CSII
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt Cardiovascular Systems
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.33 M | 1.72 M | - | - | - | - | - | - | - | 7.47 M | 12.8 M | 8.33 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 12.8 M | 1.33 M | 6.34 M |
Quarterly Long-Term Debt Cardiovascular Systems
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.11 M | 1.22 M | 1.33 M | 1.43 M | 1.52 M | 1.64 M | 1.72 M | 1.72 M | 1.94 M | 2.05 M | 15 K | 57 K | 175 K | 306 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.74 M | 7.47 M | 7.47 M | 10.4 M | 11.6 M | 12.8 M | 12.8 M | 15.4 M | 8.44 M | 8.33 M | 8.33 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 15.4 M | 15 K | 5.01 M |
Long-Term Debt of other stocks in the Medical devices industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aziyo Biologics
AZYO
|
20.4 M | - | 1.37 % | $ 20.5 M | ||
|
Bruker Corporation
BRKR
|
2.06 B | $ 38.92 | -0.89 % | $ 5.8 K | ||
|
GenMark Diagnostics, Inc.
GNMK
|
71.3 M | - | - | $ 1.77 B | ||
|
Conformis
CFMS
|
20.6 M | - | - | $ 16.4 M | ||
|
Cognyte Software Ltd.
CGNT
|
24.1 M | $ 8.16 | 4.35 % | $ 586 M | ||
|
Cutera
CUTR
|
1.06 M | - | -10.19 % | $ 1.99 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
430 K | - | -5.86 % | $ 30.6 M | ||
|
Acutus Medical
AFIB
|
32.7 M | - | -26.83 % | $ 2.62 M | ||
|
Dynatronics Corporation
DYNT
|
1.11 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
11.9 M | - | - | $ 10.2 M | ||
|
Allied Healthcare Products
AHPI
|
2.93 K | - | 3.58 % | $ 2.21 M | ||
|
Second Sight Medical Products
EYES
|
18 M | - | -0.97 % | $ 54.4 M | ||
|
EDAP TMS S.A.
EDAP
|
2.16 M | $ 4.15 | 4.01 % | $ 155 M | ||
|
AdaptHealth Corp.
AHCO
|
1.72 B | $ 9.67 | 2.87 % | $ 1.31 B | ||
|
FONAR Corporation
FONR
|
155 K | $ 18.52 | 0.11 % | $ 121 M | ||
|
Apollo Endosurgery
APEN
|
34 M | - | - | $ 475 M | ||
|
Electromed
ELMD
|
1.1 M | $ 24.25 | 1.13 % | $ 205 M | ||
|
CONMED Corporation
CNMD
|
834 M | $ 43.28 | -0.3 % | $ 1.34 B | ||
|
CryoLife, Inc.
CRY
|
290 M | - | -4.14 % | $ 702 M | ||
|
Avinger
AVGR
|
1.1 M | - | -20.74 % | $ 369 K | ||
|
AxoGen
AXGN
|
48.4 M | $ 29.18 | -2.18 % | $ 1.34 B | ||
|
Apyx Medical Corporation
APYX
|
33.2 M | $ 3.32 | 4.57 % | $ 115 M | ||
|
Axonics Modulation Technologies
AXNX
|
7.56 M | - | - | $ 3.31 B | ||
|
IRadimed Corporation
IRMD
|
1.42 K | $ 104.76 | 0.45 % | $ 1.33 B | ||
|
Itamar Medical Ltd.
ITMR
|
154 K | - | 0.03 % | $ 1.58 B | ||
|
Accuray Incorporated
ARAY
|
124 M | $ 0.53 | -0.13 % | $ 54.5 M | ||
|
Misonix, Inc.
MSON
|
38.6 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
7.64 M | - | - | $ 111 M | ||
|
Medigus Ltd.
MDGS
|
607 K | - | 10.28 % | $ 55.5 M | ||
|
Pulmonx Corporation
LUNG
|
34 M | $ 1.45 | -5.56 % | $ 56.7 M | ||
|
Cytosorbents Corporation
CTSO
|
14 M | $ 0.78 | -2.29 % | $ 42.5 M | ||
|
Medtronic PLC
MDT
|
25.6 B | $ 96.01 | -0.74 % | $ 123 B | ||
|
Align Technology
ALGN
|
88.2 M | $ 182.16 | -0.26 % | $ 13.6 B | ||
|
Intersect ENT, Inc.
XENT
|
63.6 M | - | - | $ 955 M | ||
|
Inari Medical
NARI
|
31 M | - | - | $ 4.23 B | ||
|
Butterfly Network
BFLY
|
20.4 M | $ 4.0 | 7.97 % | $ 847 M | ||
|
BIOLASE
BIOL
|
11.8 M | - | -13.19 % | $ 166 K | ||
|
Abbott Laboratories
ABT
|
9.9 B | $ 113.58 | - | $ 198 B | ||
|
NuVasive
NUVA
|
872 K | - | - | $ 2.07 B | ||
|
Nevro Corp.
NVRO
|
188 M | - | - | $ 217 M | ||
|
BioSig Technologies
BSGM
|
103 K | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
11.1 B | $ 72.71 | -1.54 % | $ 108 B | ||
|
Orthofix Medical
OFIX
|
157 M | $ 12.94 | -0.69 % | $ 512 M | ||
|
IRIDEX Corporation
IRIX
|
1.75 M | $ 1.42 | -0.7 % | $ 22.9 M |